**Abstract**

**Background**
Breast cancer is the most diagnosed cancer and the second leading cause of cancer-related deaths globally among women, frequently due to metastatic disease. CTGF orchestrates diverse molecular processes including embryonic development, wound healing, and tissue repair. CTGF promotes fibrosis in inflammatory diseases and contributes to cancer cell proliferation, migration, invasion, metastasis, and epithelial-mesenchymal transition. High CTGF is essential for tumor progression in breast cancer. CTGF inhibition has shown promise in decreasing metastatic dissemination and sensitizing cancer cells to chemotherapy in preclinical models. PH-109 (formerly RFX-109) is a self-delivering RNAi compound built on proprietary INTASY™ technology. This drug allows for silencing human CTGF with high specificity and without need for specialized formulations or drug delivery systems. PH-109 was originally developed and approved as an investigational new drug (IND) for treatment of dermatomal hyperactive scarring (Phase 2; NCT02244465) and subretinal fibrosis (Phase 3; NCT03950646). Treatment resulted in a statistically significant reduction of CTGF mRNA and protein at the treatment site, with no significant toxicity or adverse effects. Here we present proof-of-concept (PoC) in vivo data showing efficacy of intratumorally administered PH-109 in an orthotopic model of metastatic breast cancer.

**Methods**
PH-109 metabolized mRNA silencing of CTGF was validated in 4T1 cells in vitro by RT-qPCR. In vivo, 4T1 cells were implanted into the mammary fat pad of BALB/c mice. When tumors reached threshold volume (5-10 mm³), animals were randomized into treatment groups: treated animals were administered intratumorally (i Tut) on Days 1, 4, 7, 10, and 13. Vehicle (PBS), a chemically-identical non-targeting control (NTC) INTASY, or PH-109 (5 μM) were administered at the following concentrations: (0.5 μg; 2 μg) were administered to increase the amount of CHO cells isolated; doxorubicin chemotherapy (5 mg/kg) was administered intra-dermally on Days 1, 7, 13. Tumor volumes and body weights were recorded longitudinally. Primary tumors were resected from N = 6 mice at 500 mm³ in survival. Three weeks post-resection, animals were euthanized, and lungs insufflated with India ink and lung macroscopic and microscopic. Tumors continued to be recorded for N = 6 through study conclusion on Day 19.

**INTASY™ PH-109 Silences Mouse CTGF mRNA in 4T1 Mouse Mammary Carcinoma Cells in vitro**

**Figure 1.** PH-109 silences murine CTGF mRNA in 4T1 cells in vitro

PH-109 is a self-delivering therapeutic RNAi compound built on Phio’s proprietary INTASY™ platform, designed to specifically target human CTGF and carrying forward-conversion against mouse CTGF. PH-109 mediated in target concentration dependent silencing of mouse CTGF mRNA compared to PBS vehicle treated control (UTC) or chemically identical but non-targeting INTASY (NTC) in 4T1 mouse mammary cancer cells. Means ± SEM (n = 3) or ± 2 h post-treatment are shown. Means were compared to UTC by one way ANOVA and Dunnett’s post test. *p<0.05.

**IT PH-109 Treatment Before Surgery Suppresses up to ~90% of Lung Metastases Following Primary Tumor Resection**

**Figure 5.** IT PH-109 suppresses lung metastases in the 4T1 orthotopic model of metastatic mammary carcinoma

A cohort (n = 6) of animals bearing mammary fat pad 4T1 tumors had their tumors resected at each tumor reached a threshold volume of 500 mm³. Three weeks after each resection, lungs were isolated and lung macroscopic was enumerated (both faces of each lung). A. Percentage (%) of lung macrometastases for each treatment group compared to treatment with PBS. Wild-type with median and individual animals are indicated. Statistical significance assessed by one way ANOVA and Tukey’s multiple comparisons post-hoc tests. **p < 0.01, *p < 0.05, + vs PBS, + vs NTC.**

**Summary and Conclusions**
- PH-109 conveyed on-target concentration dependent silencing of mouse CTGF mRNA in 4T1 cells in vitro.
- Intratumoral (IT) PH-109 provided dose-associated primary tumor growth inhibition in an orthotopic 4T1 model of murine metastatic mammary carcinoma
- IT PH-109 conveyed similar efficacy toward primary tumor but without the toxicity (denoted by weight loss) associated with systemic doxorubicin chemotherapy.
- IT PH-109 treatment given prior to surgery robustly suppressed lung metastases.
- These studies provide proof-of-concept in vivo antitumor efficacy for IT INTASYL PH-109 targeting CTGF. PH-109 was previously evaluated in over 150 subjects without significant toxicity.
- These data in a clinically relevant orthotopic mouse model of metastatic breast cancer could support accelerated clinical investigation of PH-109 as an anticancer therapeutic.

**References**


**Figure 3.** Intratumoral (IT) PH-109 provides dose-associated primary tumor growth inhibition in an orthotopic 4T1 model of murine metastatic mammary carcinoma

4T1 tumors were seeded in the mammary fat pad. Tumor volume was assessed 3/week under treatment (arrows) with IT PH-109 (0.5 μg to 2 μg / dose, q1d through Day 15) compared to IT vehicle (PBS) or IT NTC. **p** dilution (5 μg/kg; IP; q2d through Day 15) were positive control arm. A. Mean tumor volume (mm⁴) ± SEM. N = 6 over time. B. Cumulative response was assessed by calculating tumor volume under the curve (AUC) for each animal (Day 1-19). Violin plots with medians and individual animals indicated. Statistical significance assessed by one way ANOVA and Tukey’s multiple comparisons post-hoc tests. **p** < 0.001, *p < 0.05, + vs PBS, + vs NTC.

**IT PH-109 Provides Antitumor Efficacy in an Orthotopic 4T1 Model of Murine Metastatic Mammary Carcinoma**

**Figure 2.** Schematic of in vivo model: local treatment with PH-109 in the in vivo 4T1 model of metastatic mammary cancer

*Property of PhioPharmaceuticals.*

**Figure 4.** Unlike IP doxorubicin, IT PH-109 does not elicit weight loss at doses conveying similar efficacy toward primary tumor

Percentage (%) body weight change in the orthotopic 4T1 model. Animals were weighed daily. A. Mean % weight change ± SEM (n = 12, 10) compares PBS to PH-109 and PH-109 to doxorubicin. B. **p** body weight change (AUC) Day 1-19. Violin plots with medians and individual animals are indicated. Statistical significance assessed by one way ANOVA and Tukey’s multiple comparisons post-hoc tests. **p** < 0.001, *p < 0.01, + vs PBS, + vs NTC.